September 23, 2019
Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million…